Bristol Myers Squibb (BMY) Wins FDA OK to Expand CAMZYOS to Pediatric oHCM

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its drug CAMZYOS (mavacamten). The approval allows the drug to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients weighing at least 30 kg.